Quarterly ResultMay 7, 2026, 06:41 AM
Nuvalent Q1 Net Loss $109.3M; Neladalkib NDA Submitted, Zidesamtinib PDUFA Sept 18
AI Summary
Nuvalent reported a Q1 2026 net loss of $109.3 million and R&D expenses of $83.6 million. The company announced significant pipeline progress, including the submission of an NDA for neladalkib in TKI pre-treated ALK-positive NSCLC and the ongoing FDA review of zidesamtinib's NDA for TKI pre-treated ROS1-positive NSCLC with a PDUFA date of September 18, 2026. Nuvalent also plans a label expansion submission for zidesamtinib in TKI-naïve ROS1-positive NSCLC in H2 2026 and continues enrollment in its ALKAZAR and HEROEX-1 trials. The company strengthened its leadership team with two key promotions and maintains a strong cash position of $1.3 billion, sufficient to fund operations into 2029.
Key Highlights
- NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC.
- Zidesamtinib NDA for TKI pre-treated ROS1-positive NSCLC under FDA review; PDUFA target date Sept 18, 2026.
- Q1 2026 Net Loss was $(109.3) million, compared to $(84.6) million in Q1 2025.
- Q1 2026 Research and Development expenses increased to $83.6 million from $74.4 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $1.3 billion as of March 31, 2026.
- Existing cash is expected to fund operations into 2029.
- Plans to submit data for zidesamtinib label expansion in TKI-naïve ROS1-positive NSCLC in H2 2026.
- Benjamin Lane promoted to Chief Technology Operations Officer; Kirsten Duncan to VP, Medical Affairs.